Current risks of viral hepatitis from blood transfusions

The cost of blood transfusions in cancer patients: a reanalysis of a Canadian economic evaluation

Background. Cancer patients undergoing chemotherapy are at an increased risk for anemia. Hence, they are high consumers of allogenic blood transfusions. In 1997, an economic evaluation was undertaken at the Princess Margaret Hospital to estimate the cost of a transfusion in cancer patients. The analysis relied on published costing information and on an internal review of patient resource utilization. Overall, the cost of a blood transfusion was estimated at Can$599. Since 1997, there have been some major changes in the management of Canada's blood supply and within the Princess Margaret Hospital.

Methods. In order to evaluate how these changes affected the cost of a transfusion in cancer patients, the original 1997 economic database was reanalyzed using updated 1999 costing information obtained from Canadian Blood Services (CBS) and from the Princess Margaret Hospital.

Results. The reanalysis suggested that the cost of a blood transfusion in cancer patients increased from Can$599 in 1997 to Can$731 in 1999. The major incremental costs responsible for this increase were additional screening tests, increased opportunity costs for donors and a modest rise in distribution and administration within the hospital. Costs that were no longer relevant in 1999 were the cost of treating transfusion-related infections.

Conclusions. These results support the findings of the original publication that a unit of blood is a highly resource intensive commodity which requires that each blood unit be used appropriately. Therefore, preventative strategies that would reduce the use of blood products have to be identified and implemented.

Identification of risk factors for hepatitis B and C in Peshawar, Pakistan

Background

Hepatitis B and C need immediate worldwide attention as the infection rates are too high. More than 240 million people have chronic (long-term) liver infections. Every year, about 600,000 people die globally due to the acute or chronic consequences of hepatitis B and more than 350,000 people die from hepatitis C-related liver diseases.

Methods

Our study was designed as a case-control, descriptive study. It was conducted through formal interviews by using structured questionnaires. A total of 100 cases were included, with four controls for each case.

Results

This study confirms household contact, history of dental work, history of surgery, sexual contact, and history of transfusion (blood and its components) as the main risk factors which are responsible for the increased prevalence of hepatitis.

Conclusion

The important risk factors, responsible for the high prevalence of hepatitis B and C in our society are household contact, history of dental work, history of surgery, sexual contact, and history of transfusion (blood and its components). The odds ratio of probability for these risk factors are: 4.2 for household contact history, 4.1 for history of dental work, 3.9 for sexual contact, 2.7 for history of surgery, and 2.1 for history of transfusion. Associations of other predictor variables (diabetes status, education level, profession, contact sports, intravenous drug abuse, residence, immunosuppression, and skin tattoos) were not statistically significant.

Enhanced surveillance of acute hepatitis B and C in four health regions in Canada, 1998 to 1999

OBJECTIVE

To assess the incidence and risk factors for acute hepatitis B and acute hepatitis C in a defined Canadian population.

PATIENTS AND METHODS

An enhanced surveillance system was established in October 1998 to identify cases of acute hepatitis B and C infections in four regions in Canada, with a total population of approximately 3.2 million people. Information on demographic and clinical characteristics, laboratory results and potential risk factors was collected using predefined questionnaires.

RESULTS

A total of 79 cases of acute hepatitis B and 102 cases of acute hepatitis C were identified from October 1998 to December 1999, resulting in an incidence rate of 2.3 and 2.9/100,000 person-years, respectively. Males had higher incidence rates than females. The incidence of acute hepatitis B peaked at age 30 to 39 years for both males and females, whereas acute hepatitis C peaked at 30 to 39 years for males and 15 to 29 years for females. At least 34% of acute hepatitis B and 63% of acute hepatitis C were associated with injection drug use. Persons who were 15 to 39 years of age were more likely to report injection drug use as a risk factor. Heterosexual contact was reported to be a risk factor for 36.6% of acute hepatitis B cases and 3.5% of acute hepatitis C cases.

CONCLUSIONS

The surveillance provides national incidence estimates of clinically recognized acute hepatitis B and C. Both hepatitis B and C are important public health threats to Canadians. Prevention efforts for both diseases should focus on injection drug use, especially for people aged 15 to 39 years. Risky sexual behaviour is also a major concern in prevention of hepatitis B in Canada.

Blood transfusion risks in the intensive care unit

This article reviews transfusion risks with particular emphasis on the critically ill. It describes the various types of noninfectious,infectious, and mild-to-severe reactions that can occur in a trans-fused patient. The article describes differential diagnosis of these reactions and the handling and treatment of the patient. Diagnosis of the type of transfusion reaction by laboratory tests is detailed. Finally, the article discusses the dangers of human error with possible strategies to combat this problem using new technologies.